Electrochemical Biosensor Rapidly Detects Cerebrospinal Fluid Leaks

An enzyme-based electrochemical sensor detected a CSF leak marker in patient samples within 95 minutes.

Image: Figure from the study in International Journal of Molecular Sciences, CC BY 4.0

Source: Labmedica.com (October 14, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.

Key takeaways

  • SKKU and Samsung Medical Center built an electrochemical sensor for β₂-transferrin, a marker associated with cerebrospinal fluid leaks.
  • The gold nanostructured sensor detected 0.135 μg/mL and correlated with conventional methods in patient CSF samples at R² 0.912.
  • Additional clinical validation is needed before the palm-sized reader can be developed for emergency diagnostic use.

Researchers at Sungkyunkwan University and Samsung Medical Center in South Korea have developed an electrochemical biosensor designed to detect cerebrospinal fluid leaks in 95 minutes. The system identifies β₂-transferrin, a form of a blood protein associated with cerebrospinal fluid, by sensing subtle differences in sugars on the protein's surface. In patient cerebrospinal fluid samples, its measurements correlated strongly with conventional precision analytical methods. The work could support faster assessment of suspected leaks after severe head trauma or brain surgery, although further clinical validation is planned.

Detecting a difficult-to-distinguish fluid

Cerebrospinal fluid, or CSF, cushions the brain and spinal cord. A defect in the skull after injury or surgery can allow this fluid to leak through the nose or ears, creating a clinical problem that needs prompt identification.

Diagnosis is challenging because the relevant marker, β₂-transferrin, closely resembles ordinary transferrin found in blood. The key difference is not the protein's main structure, but the sugar molecules attached to its surface. β₂-transferrin lacks terminal sugars called sialic acids.

Using an enzyme as a molecular inspector

The platform, called ESGNS, looks for the empty attachment sites left behind when sialic acids are absent. It works somewhat like checking whether reserved seats in a theater are open or occupied: the sensor does not need to inspect every feature of the protein, only whether a particular site is available.

The team used an enzyme called α-2,3-sialyltransferase to recognize those exposed sites and add new sugar molecules. That reaction produces an electrical signal. On normal transferrin, the relevant sites are already occupied, so the enzyme does not generate the same response.

Amplifying a faint electrical readout

The biosensor uses gold nanostructured electrodes to strengthen weak electrochemical signals. These nanoscale electrode surfaces are intended to help the device operate in complicated biological samples, including blood and other body fluids, where many molecules can interfere with measurement.

The system detected its target at concentrations as low as 0.135 μg/mL. In tests with patient CSF samples, results had an R² value of 0.912 compared with conventional precision analytical methods. An R² value measures how closely two sets of measurements track each other, with 1 representing a perfect match.

A portable format for potential bedside testing

The researchers paired the sensor with a compact, palm-sized reader, creating a format intended for potential point-of-care testing. Rather than requiring a sample to travel through a lengthy laboratory workflow, such a device could eventually bring measurement closer to the patient.

Professor Jinsung Park of Sungkyunkwan University's Department of Biomechatronic Engineering said the work selectively converts small protein-sugar differences into electrical signals. The team aims to develop the technology for emergency diagnostics after additional clinical validation and to explore other diseases linked to altered protein glycosylation, the pattern of sugars attached to proteins.

Why This Matters

This work makes the sensing platform itself central to the diagnostic challenge. By targeting a biochemical feature that differentiates CSF-associated β₂-transferrin from ordinary transferrin, the device offers a distinct route to recognizing leaks that can be difficult to confirm. Its reported performance in patient samples is encouraging, but broader clinical testing will determine how well the portable system performs across real emergency-care settings.

The study was published in Chemical Engineering Journal. The next step is validation that establishes whether the 95-minute assay can reliably guide clinical decisions beyond the samples evaluated so far.

Topics: Biosensors · Diagnostics & precision medicine

Start here: Biosensors explained